A Randomized, Placebo- and Positive-Controlled, Crossover Study to Evaluate the Effect of Meropenem-Vaborbactam on the QT/QTc Interval in Healthy Volunteers
Phase of Trial: Phase I
Latest Information Update: 17 Jan 2019
Price : $35 *
At a glance
- Drugs Meropenem/vaborbactam (Primary) ; Moxifloxacin
- Indications Bacteraemia; Gram-negative infections; Intra-abdominal infections; Nosocomial pneumonia; Pneumonia; Pyelonephritis; Urinary tract infections
- Focus Adverse reactions
- Sponsors Melinta Therapeutics
- 09 Jan 2019 Status changed from active, no longer recruiting to completed.
- 06 Nov 2018 Status changed from recruiting to active, no longer recruiting.
- 15 Oct 2018 Planned End Date changed from 31 Aug 2018 to 31 Dec 2018.